Scholarlink

<p>Protein ubiquitination is among the most important posttranslational modifications in eukaryotes. It precisely regulates protein stability and cellular signaling through the ubiquitin‒proteasome system (UPS). A dynamic equilibrium network formed by the E1-E2-E3 enzymatic cascade and deubiquitinating enzymes (DUBs) plays a central role in cell cycle regulation, DNA damage repair, and signal transduction. In tumorigenesis and cancer progression, the UPS regulates key factors such as p53 and p27 to control cell proliferation and apoptosis. It is involved in the activation of oncogenic pathways, including the PI3K/Akt, Wnt/β-catenin, and NF-κB pathways, and regulates cancer stem cell maintenance and tumor immune microenvironment remodeling. On the basis of these mechanisms, significant progress has been made in therapeutic strategies targeting the UPS. Proteasome inhibitors have become standard treatments for multiple myeloma. Proteolysis-targeting chimera (PROTAC) technology overcomes the limitations of “undruggable” targets and enables the specific degradation of pathogenic proteins such as the androgen receptor (AR) and estrogen receptor (ER). Molecular glue degraders exert antitumor effects by reshaping the substrate recognition interface of E3 ligases. E3 ligase inhibitors and DUB inhibitors are also entering clinical development. However, the selective toxicity, pharmacokinetic limitations of PROTACs, and acquired resistance remain major challenges. Future research should focus on optimizing drug design and delivery strategies to reduce systemic toxicity and establish a ubiquitination biomarker-guided precision medicine framework.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ubiquitination in cancer: mechanisms, signaling networks and potential therapeutic opportunities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Yan Xue,
  • Huiying Wu,
  • Wu Liu

摘要

Protein ubiquitination is among the most important posttranslational modifications in eukaryotes. It precisely regulates protein stability and cellular signaling through the ubiquitin‒proteasome system (UPS). A dynamic equilibrium network formed by the E1-E2-E3 enzymatic cascade and deubiquitinating enzymes (DUBs) plays a central role in cell cycle regulation, DNA damage repair, and signal transduction. In tumorigenesis and cancer progression, the UPS regulates key factors such as p53 and p27 to control cell proliferation and apoptosis. It is involved in the activation of oncogenic pathways, including the PI3K/Akt, Wnt/β-catenin, and NF-κB pathways, and regulates cancer stem cell maintenance and tumor immune microenvironment remodeling. On the basis of these mechanisms, significant progress has been made in therapeutic strategies targeting the UPS. Proteasome inhibitors have become standard treatments for multiple myeloma. Proteolysis-targeting chimera (PROTAC) technology overcomes the limitations of “undruggable” targets and enables the specific degradation of pathogenic proteins such as the androgen receptor (AR) and estrogen receptor (ER). Molecular glue degraders exert antitumor effects by reshaping the substrate recognition interface of E3 ligases. E3 ligase inhibitors and DUB inhibitors are also entering clinical development. However, the selective toxicity, pharmacokinetic limitations of PROTACs, and acquired resistance remain major challenges. Future research should focus on optimizing drug design and delivery strategies to reduce systemic toxicity and establish a ubiquitination biomarker-guided precision medicine framework.